Find company announcements below, or check out the latest news in the right side menu.
30. January 2009
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transaction under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
28. January 2009
22. January 2009
Strong 2008 performance. New, increased long-term targets. Growth expectations for 2009.2008 sales growth was strong at 13% in local currencies. Earnings were also very satisfactory. Lower growth in the fourth quarter. Expected sales growth in 2009 of 8–13% in DKK in an uncertain mar
31. October 2008
Nine months into 2008 sales growth remains strong at 16% in local currencies. Earnings also developed well, with an operating margin of 18.5%. Expected full-year sales and earnings growth are increased in DKK due to improved exchange rates.
Novozymes hereby announce that Hans Werdelin in relation to his 70th birthday has decided to retire from Novozymes' Board of Directors effective as per October 31, 2008.
18. September 2008
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
14. August 2008
Halfway into 2008, sales growth has remained high within both enzymes and microorganisms, totaling 16% in local currencies (LCY). Earnings for the period are satisfactory, despite low realized exchange rates and high raw material prices.
24. April 2008
2008 kicked off with high sales growth, leading to an upwards adjustment in local currencies. Expected sale of enzymes for detergents and feed significantly increased. Despite unfavorable exchange rates, the outlook for net profit 2008 in DKK is maintained.
6. March 2008
Novozymes A/S yesterday held its Annual Meeting of Shareholders, at which the report on the Company’s operations in the last financial year was adopted.
8. February 2008
5. February 2008
On January 31, 2008, Novozymes received information that ATP and ATP Invest, Kongens Vænge 8, 3400 Hillerød, Denmark reduced its holdings of Novozymes shares to 3,203,971 B shares.
31. January 2008
30. January 2008
25. January 2008
2007 was a really good year for Novozymes. Growth was the theme of the year, with sales growth higher than expected at 14%. The financial results were satisfactory, particularly in the light of high energy and raw material prices. Unfavorable exchange rate movements had a negative impact on the resu
10. December 2007
Novozymes Biologicals Holding A/S has taken up these shares, which represent approximately 98% of the common shares of Philom Bios, and will pay for these shares today by providing the depositary with sufficient funds for transmittal to the holders of these shares.
3. December 2007
30. November 2007
28. November 2007
26. November 2007
23. November 2007
1. November 2007
31. October 2007
Today Novozymes Biologicals Holding A/S, a wholly-owned subsidiary of Novozymes A/S, (“Novozymes”), has signed a pre-acquisition agreement with Philom Bios Inc. (“Philom Bios”),
25. October 2007
Satisfactory growth and earnings for Novozymes. Sales rose by 15% in the first nine months, while growth in DKK was 11%. Operating profit rose by 14% challenged by unfavorable exchange rate movements and rising raw material and energy prices.
10. December 2013
| Copyright © 2013 Novozymes. All Rights Reserved.